Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials

2011; Oxford University Press; Volume: 24; Issue: 5 Linguagem: Inglês

10.1038/ajh.2011.8

ISSN

1941-7225

Autores

Giuliano Tocci, Francesco Paneni, Francesca Palano, Sebastiano Sciarretta, Andrea Ferrucci, Theodore W. Kurtz, Giuseppe Mancia, Massimo Volpe,

Tópico(s)

Heart Failure Treatment and Management

Resumo

BackgroundTo determine whether the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) on top of standard cardiovascular (CV) therapies may reduce the incidence of new onset diabetes (NOD) in placebo-controlled clinical trials. The effects of these drugs on CV and non-CV mortality were also tested.

Referência(s)